Evidence map›Paper›PMID 36133821›Full record

ArticleFrontiers in pharmacology2022

α2-macroglobulin-rich serum as a master inhibitor of inflammatory factors attenuates cartilage degeneration in a mini pig model of osteoarthritis induced by "idealized" anterior cruciate ligament reconstruction.

Ruipeng Zhao, Xiaochun Wei, Chengming Zhang, Hongru Wu, Chuan Xiang, Haoqian Li, Wangping Duan, Zhiqing Duan, Chunjiang Li, Yu Zhao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Regenerative Medicine: The Next Generation of Autologous Blood Formulations.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ruipeng ZhaoDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Xiaochun WeiDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Chengming ZhangDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Hongru WuShanxi Institute of Sports Science, Taiyuan, China.
Chuan XiangDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Haoqian LiDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Wangping DuanDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Zhiqing DuanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China.
Chunjiang LiDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Yu ZhaoDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Lingan HuangDepartment of Orthopaedics, The Second Hospital of Shanxi Medical University. Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair, Taiyuan, China.
Shanxi Medical University · CNSecond Hospital of Shanxi Medical University · CNShanghai Research Institute of Sports Science · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-traumatic osteoarthritis is a special type of osteoarthritis and a common disease, with few effective treatments available. α2-Macroglobulin (α2M) is important to chondral protection in post-traumatic osteoarthritis. However, its injection into xenogeneic joint cavities involves safety hazards, limiting clinical applications. Exploring serum α2M-enriching strategies and the therapeutic effect and mechanism of α2M-rich serum (α2MRS) autologous joint injection to treat post-traumatic osteoarthritis has significant value. In the present study, a unique filtration process was used to obtain α2MRS from human and mini pig serum. We evaluated the potential of α2MRS in protecting against post-surgery cartilage degeneration. We identify the potential of α2MRS in reducing the expression of inflammatory cytokines and factors that hasten cartilage degeneration in post-operative conditions leading to post-traumatic osteoarthritis. The potential of α2MRS was analyzed in interleukin-1β induced human chondrocytes and mini pig models. In the chondrocyte model, α2MRS significantly promoted human chondrocyte proliferation and reduced apoptosis and chondrocyte catabolic cytokine gene transcription and secretion. The anterior cruciate ligament autograft reconstruction model of mini pigs was randomized into groups, operated on, and injected with α2MRS or saline. The results showed that α2MRS injection significantly suppressed the levels of inflammatory factors, improved gait, and showed significantly lower cartilage degeneration than the groups that did not receive α2MRS injections. This study highlights the chondroprotective effects of α2MRS, elucidated its potential applications against cartilage degeneration, and could provide a basis for the clinical translation of α2MRS.

Indexed as

anterior cruciate ligamentarticular cartilageinflammationmini pigosteoarthritisα2M-rich serum

Identifiers

PMID36133821
PMCPMC9483147
OpenAlexW4294605774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.